United Kingdom-based ViiV Healthcare has started a trial to identify and evaluate approaches for implementing its once-monthly injectable treatment for HIV into clinical practice, it was reported yesterday.

The company stated that its team will work with clinical staff at different sites across the United States to conduct its one-year CUSTOMIZE trial (cabotegravir plus rilpivirine in the US to optimise and measure implementation and experience).

In April 2019, the company submitted a new drug application to the US Food and Drug Administration (FDA) for the two-drug regimen of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) intended to treat HIV-1 infection in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine. Edurant (rilpivirine) is a prescription medicine, used with other antiretroviral medicines for the treatment of human immunodeficiency virus-1 (HIV-1) in people 12 years of age and older and who weigh around 77lbs (35kg).

The company is currently recruiting patients in medical clinics in nine US cities, which have been selected to create a representative sample of clinic types.